The randomised phase II Microtec Study evaluated the cumulative incidence of VTE in advanced cancer with lower levels of tissue factor EVs not on thromboprophylaxis enoxaparin (LMWH) compared to patients with higher tissue factor EVs (TF‐EVs) randomised to enoxaparin or observation [63]. This evidence concerns the gene TF and cancer.